Clinical Trial Update: Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Biphasic Insulin Aspart 30 in Type 2 diabetes patients failing oral therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Biphasic insulin aspart 30 (insulin aspart, biphasic 30/70)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED